Abstract:Introduction: The prognosis for glioma is generally poor, and the 5-year survival rate for patients with this disease has not shown significant improvement over the past few decades. Parkinson's disease (PD) is a prevalent movement disorder, ranking as the second most common neurodegenerative disease after Alzheimer's disease. Although Parkinson's disease and glioma are distinct diseases, they may share certain underlying biological pathways that contribute to their development. Objective: This study aims to investigate the involvement of genes associated with Parkinson's disease in the development and prognosis of glioma. Methods: We obtained datasets from the TCGA, CGGA, and GEO databases, which included RNA sequencing data and clinical information of glioma and Parkinson's patients. Eight machine learning algorithms were used to identify Parkinson-Glioma feature genes (PGFGs). PGFGs associated with glioma prognosis were identified through univariate Cox analysis. A risk signature was constructed based on PGFGs using Cox regression analysis and the Least Absolute Shrinkage and Selection Operator (LASSO) method. We subsequently validated its predictive ability using various methods, including ROC curves, calibration curves, KM survival analysis, C-index, DCA, independent prognostic analysis, and stratified analysis. To validate the reproducibility of the results, similar work was performed on three external test datasets. Additionally, a meta-analysis was employed to observe the heterogeneity and consistency of the signature across different datasets. We also compared the differences in genomic variations, functional enrichment, immune infiltration, and drug sensitivity analysis based on risk scores. This exploration aimed to uncover potential mechanisms of glioma occurrence and prognosis. Results: We identified 30 PGFGs, of which 25 were found to be significantly associated with glioma survival. The prognostic signature, consisting of 19 genes, demonstrated excellent predictive performance for 1-, 2-, and 3-year overall survival (OS) of glioma. The signature emerged as an independent prognostic factor for glioma overall survival (OS), surpassing the predictive performance of traditional clinical variables. Notably, we observed differences in the tumor microenvironment (TME), levels of immune cell infiltration, immune gene expression, and drug resistance analysis among distinct risk groups. These findings may have significant implications for the clinical treatment of glioma patients. Conclusion: The expression of genes related to Parkinson's disease is closely associated with the immune status and prognosis of glioma patients, potentially regulating glioma pathogenesis through multiple mechanisms. The interaction between genes associated with Parkinson's disease and the immune system during glioma development provides novel insights into the molecular mechanisms and targeted therapies for glioma.

Identification of a Gene Signature Associated with Radiotherapy and Prognosis in Gliomas.

Transcriptomic Profiling Identifies a Nucleotide Metabolism-Related Signature with Prognostic Power in Gliomas

Comprehensive Analysis of Multi-Omics Data of Recurrent Gliomas Identifies a Recurrence-Related Signature As a Novel Prognostic Marker.

A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway.

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

An Integrated Mrna and Microrna Expression Signature for Glioblastoma Multiforme Prognosis.

Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma

Identification and Validation of a 17-Gene Signature to Improve the Survival Prediction of Gliomas

Development and validation of an immune-related gene signature for predicting the radiosensitivity of lower-grade gliomas

Development of a Prognostic Five-Gene Signature with Radiotherapy Guidance Significance for Diffuse Lower-Grade Glioma Patients Based on Large-Scale Sequencing Data

Construction of a novel radiosensitivity- and ferroptosis-associated gene signature for prognosis prediction in gliomas

Integrated Analysis to Evaluate the Prognostic Value of Signature Mrnas in Glioblastoma Multiforme

Integrating Radiosensitivity Gene Signature Improves Glioma Outcome and Radiotherapy Response Prediction

Prognosis and therapeutic significance of IGF-1R-related signaling pathway gene signature in glioma

A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy

An Integrated Immune-Related Bioinformatics Analysis in Glioma: Prognostic Signature's Identification and Multi-Omics Mechanisms' Exploration

Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme

Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study

Upregulation of DNA Metabolism-Related Genes Contributes to Radioresistance of Glioblastoma.

Identification and validation of a novel Parkinson-Glioma feature gene signature in glioma and Parkinson's disease

Identification of an IFN-β-associated Gene Signature for the Prediction of Overall Survival among Glioblastoma Patients